Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and glofitamab (glofit) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)

被引：0
|
作者：
Locke, F. L. [1 ]
Chen, J. M. [2 ]
Chan, K. [2 ]
Ray, M. D. [3 ]
Zhang, I. [4 ]
Keeping, S.
Fu, C. [5 ]
Patel, A. R. [3 ]
Oluwole, O. O. [6 ]
机构：
[1] Univ S Florida, Blood & Marrow Transplant & Cellular Immunother, H Lee Moffitt Canc Ctr, Tampa, FL USA
[2] PRECISIONheor, Evidence Synth, Vancouver, BC, Canada
[3] Gilead Co, Hlth Econ Outcomes Res, Kite, Santa Monica, CA USA
[4] PRECISIONheor, Evidence Synth, Oak- Iand, CA USA
[5] Gilead Co, US Med Affairs, Kite, Santa Monica, CA USA
[6] Vanderbilt Univ, Hematol Oncol, Med Ctr, Nashville, TN USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.703
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
839P
引用
收藏
页码：S549 / S549
页数：1
相关论文
共 50 条
  • [1] Matching- adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
    Oluwole, O. O.
    Ray, M. D.
    Chen, J. M.
    Chan, K.
    Zhang, I.
    Keeping, S.
    Smith, H.
    Spooner, C. L. Bellasis
    Patel, A. R.
    Locke, F. L.
    ANNALS OF ONCOLOGY, 2023, 34 : S548 - S548
  • [2] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Maloney, David G.
    Kuruvilla, John
    Fox, Christopher P.
    Cartron, Guillaume
    Li, Daniel
    Hasskarl, Jens
    Bonner, Ashley
    Zhang, Yixie
    Liu, Fei Fei
    BLOOD, 2020, 136
  • [3] Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy
    Oluwole, Olalekan O.
    Chen, Jenny M. H.
    Chan, Keith
    Patel, Anik R.
    Jansen, Jeroen P.
    Keeping, Sam
    Bashir, Zahid
    Zheng, Yan
    Snider, Julia
    Locke, Frederick L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S388 - S388
  • [4] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
    Topp, Max S.
    van Meerten, Tom
    Houot, Roch
    Minnema, Monique
    Milpied, Noel
    Lugtenburg, Pieternella J.
    Thieblemont, Catherine
    Wermke, Martin
    Song, Kevin
    Avivi, Irit
    Kuruvilla, John
    Duehrsen, Ulrich
    Chu, Rachel
    Zheng, Lianqing
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S101 - S101
  • [5] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
    Abramson, Jeremy S.
    Kamdar, Manali
    Liu, Fei Fei
    Crotta, Alessandro
    Previtali, Alessandro
    Klijn, Sven L.
    Wang, Pearl
    Situ, Aaron
    Zhang, Yixie
    Bonner, Ashley
    Lunning, Matthew A.
    BLOOD, 2022, 140 : 4655 - 4656
  • [6] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
    Topp, Max S.
    van Meerten, Tom
    Hout, Roch
    Minnema, Monique C.
    Milpied, Noel
    Lugtenburg, Pieternella J.
    Thieblemont, Catherine
    Wermke, Martin
    Song, Kevin W.
    Avivi, Irit
    Kuruvilla, John
    Duehrsen, Ulrich
    Chu, Rong
    Zheng, Lianqing
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    MOLECULAR THERAPY, 2020, 28 (04) : 577 - 577
  • [7] Matching-Adjusted Indirect Comparison of Axicabtagene Ciloleucel vs Odronextamab for the Treatment of Relapsed/Refractory (R/R) Large B- Cell Lymphoma (LBCL) After 2 Prior Lines of Systemic Treatment
    Locke, Frederick L.
    Popoff, Evan
    Wade, Sally W.
    Limbrick-Oldfield, Eve
    Kanters, Steve
    Palivela, Madhu
    Best, Timothy
    Ray, Markqayne
    Oluwole, Olalekan O.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S478 - S478
  • [8] Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma
    Oluwole, Olalekan O.
    Chen, Jenny M. H.
    Chan, Keith
    Patel, Anik R.
    Jansen, Jeroen P.
    Keeping, Sam
    Zheng, Yan
    Snider, Julia T.
    Locke, Frederick L.
    LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3052 - 3062
  • [9] AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)
    Diakite, I
    Lin, V. W.
    Klijn, S.
    Navale, L.
    Purdum, A. G.
    Fenwick, E.
    Botteman, M.
    van Hout, B.
    VALUE IN HEALTH, 2019, 22 : S41 - S41
  • [10] Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
    Topp, Max S.
    van Meerten, Tom
    Wermke, Martin
    Lugtenburg, Elly J.
    Minnema, Monique C.
    Song, Kevin W.
    Thieblemont, Catherine
    Jiang, Yizhou
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345